TaiwanJ Pharmaceuticals
Zhubei, Taiwan· Est.
TaiwanJ develops small‑molecule drugs for liver and inflammatory diseases using proprietary TLR4/Autotaxin platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
TaiwanJ develops small‑molecule drugs for liver and inflammatory diseases using proprietary TLR4/Autotaxin platforms.
Liver diseaseInflammationOncology
Technology Platform
Proprietary small‑molecule discovery targeting TLR4, autotaxin, NOX, and HDAC to modulate fibrosis, inflammation, and tumor pathways.
Opportunities
Advancing JKB‑122 into Phase 3 could capture a sizable share of the NAFLD market, while the platform enables rapid entry into fibrosis and oncology indications.
Risk Factors
Early‑stage clinical data, regulatory uncertainty, and competition from larger pharma companies developing NAFLD therapeutics pose significant risks.
Competitive Landscape
TaiwanJ competes with firms such as Intercept Pharmaceuticals and Madrigal Biopharma; its differentiation lies in a small‑molecule, multi‑target approach versus biologics and RNA‑based therapies.